SML2260
Taspoglutide trifluoroacetate salt
≥95% (HPLC), GLP-1 receptor agonist, lyophilized powder
别名:
8-(2-Methylalanine)-35-(2-methylalanine)-36-L-argininamide-7-36-glucagon-like peptide I (human) trifluoroacetate salt, BIM 51077 trifluoroacetate salt, R1583 trifluoroacetate salt, RO 5073031 trifluoroacetate salt, [Aib8,35]hGLP-1(7-36)NH2; H-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2 trifluoroacetate salt
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C152H232N40O45 · xC2HF3O2
化学文摘社编号:
分子量:
3339.71 (free base basis)
UNSPSC Code:
51111800
NACRES:
NA.77
产品名称
Taspoglutide trifluoroacetate salt, ≥95% (HPLC)
assay
≥95% (HPLC)
form
lyophilized powder
color
white to beige
shipped in
wet ice
storage temp.
−20°C
Biochem/physiol Actions
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. Taspoglutide improves glucose tolerance, postprandial glucose, body weight, glycaemic control and insulin sensitivity in the Zucker diabetic fatty rat.
long-acting glucagon-like peptide 1 (GLP-1) receptor agonist
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
S R K Seshasai et al.
Diabetes, obesity & metabolism, 17(5), 505-510 (2015-02-07)
To study the short-term cardiovascular effects of the once-weekly glucagon-like peptide-1 receptor agonist taspoglutide. We conducted a meta-analysis of individual-participant data from nine randomized controlled trials in the T-Emerge programme, which assessed the efficacy and safety of taspoglutide in type
E Sebokova et al.
Diabetes, obesity & metabolism, 12(8), 674-682 (2010-07-02)
Glucagon-like peptide-1 (GLP-1) receptor agonists are a novel class of pharmacotherapy for type 2 diabetes. We investigated the effects of a novel, long-acting human GLP-1 analogue, taspoglutide, in the Zucker diabetic fatty (ZDF) rat, an animal model of type 2
K Pabreja et al.
British journal of pharmacology, 171(5), 1114-1128 (2013-07-31)
The incidence of type 2 diabetes in developed countries is increasing yearly with a significant negative impact on patient quality of life and an enormous burden on the healthcare system. Current biguanide and thiazolidinedione treatments for type 2 diabetes have
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持